Mirati Therapeutics Inc $ 204.57 3.65 (1.82%)
Volume:
158,064
Avg Vol (1m):
432,254
Market Cap $:
10.30 Bil
Enterprise Value $:
9.72 Bil
PE Ratio:
0.00
PB Ratio:
16.66
Financial Strength | 9/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | No Debt | ||
Equity-to-Asset | 0.89 | ||
Interest Coverage | No Debt | ||
Piotroski F-Score | 3 | ||
Altman Z-Score | 84.93 | ||
Beneish M-Score | -1.64 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -2763.98 | ||
Net Margin % | -2690.19 | ||
ROE % | -62.51 | ||
ROA % | -56.66 | ||
ROC (Joel Greenblatt) % | -12339.22 | ||
3-Year EBITDA Growth Rate | -11.9 | ||
3-Year EPS without NRI Growth Rate | -10.7 |
MRTX
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 16.66 | ||
PS Ratio | 745.15 | ||
EV-to-EBIT | -28.79 | ||
EV-to-EBITDA | -28.84 | ||
EV-to-Revenue | 795.95 | ||
Current Ratio | 8.84 | ||
Quick Ratio | 8.84 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -25.6 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 16.66 | ||
Earnings Yield (Greenblatt) % | -3.48 |